have become increasingly useful in the management of cardiovascular diseases. The Heart Outcomes Prevention Evaluation (HOPE) study showed a significant reduction in cardiovascular endpoints when high-risk patients were given ACE inhibitors (ACE-I). Though controversy exists, angiotensin II receptor blockers (ARBs) may be almost as beneficial as ACE-Is in heart failure, renal microalbuminuria and in endothelial protection. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomised Assessment Study in ACE-iNtolerant subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) will confirm whether ACE-Is and ARBs are equivalent in cardiovascular protection. Change in the use of Renin-Angiotensin System Blockers in Older Patients Fulfilling the HOPE Criteria